Skip to content
Search

Latest Stories

Submit Guest Post

UK injects over £40 million into vaccine projects set for human trials

THE UK government has announced a £20-million funding for a Oxford University project on a Covid-19 vaccine, which is set for human trials from Thursday, and £22.5 million for Imperial College London to support its clinical trials.

Health Secretary Matt Hancock told the daily Downing Street briefing on Tuesday (21) that the health department was “throwing everything” at trying to find a vaccine because it is a critical aspect of the Covid-19 pandemic fight and lifting the strict lockdown measures in place to curb its spread.


"Both of these promising projects are making rapid progress, and I have told the scientists leading them that we will do everything in our power to support," he said, adding that it normally "would take years to get to this point."

"The UK is at the forefront of the global effort – we've put in more money than any other into the global search for a vaccine. Nothing about this is inevitable. Vaccine production is a matter of trial and error. But the UK will throw everything it has at trying to find one."

The announcement came as UK had another major daily leap in the hospital death toll from coronavirus, up by 823 to hit 17,337 by Tuesday.

Hancock said the government's plan to control the rapid spread of the virus and prevent the NHS from being overwhelmed was working as the rate of hospitalisations with Covid-19 was showing a downward trajectory.

He also maintained that the problems over PPE shortage were being addressed by actively engaging with thousands of companies, including 159 manufacturers in the UK.

“We are determined to get people the PPE they need. This is a 24/7 operation, one of the biggest cross-government operation I have ever seen," said Hancock.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

PCOS

PCOS must be recognised as a chronic condition

iStock

Why PCOS poses a greater long-term health risk for South Asian women

Dr Kalpana Purshottamdas Lakhani

PCOS is often dismissed as a reproductive issue, but for south Asian women the consequences reach far beyond the ovary — affecting metabolic health, fertility, and lifelong wellbeing.

Polycystic ovary syndrome (PCOS) is one of the most common hormonal conditions in women, affecting an estimated 8–13% worldwide. But for south Asian women, the impact is even greater — and far less recognised. Research shows that south Asian women have higher insulin resistance, develop type 2 diabetes five to ten years earlier than white European women, and experience more severe metabolic features when they have PCOS. They also face higher rates of gestational diabetes and earlier cardiovascular risk. These differences make the long-term consequences of PCOS particularly significant in this community.

Keep ReadingShow less